The Added Value of CT Scanning in Patients With an Unilateral Pleural Effusion
NCT ID: NCT03270215
Last Updated: 2020-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
232 participants
OBSERVATIONAL
2017-10-01
2019-01-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Is CT-scanning better than chest x-ray plus a thoracocentesis for discriminating malignant from benign pleural effusions?
2. What is the added value of a CT-scanning to chest x-ray plus thoracocentesis for discriminating malignant from benign pleural effusions?
The above measured as, true positive, true negative, false positive, false negative, sensitivity, specificity, likelihood ratio+, likelihood ratio -, positive predictive value, negative predictive value and diagnostic accuracy.
Study design A retrospective diagnostic study including consecutive patients with a unilateral pleural effusion. Thoracocentesis, chest x-ray and CT findings are categorised as either normal (i.e. not suggestive of any aetiology of the unilateral pleural effusion), suggestive of other lung pathology or suggestive of malignancy (i.e. representing a possible aetiology of the unilateral pleural effusion). The final diagnosis is extracted from the patients' electronic medical records. When no diagnosis is found, two investigators agree on a consensus diagnosis based on all investigation results. If no reasonable diagnosis can be established based on the findings, the patient case is categorised as having no final diagnosis.
The investigators follow the STARD guideline for reporting diagnostic accuracy studies.
Patients The investigators will include consecutive patients presenting with a unilateral pleural effusion between 01 January 2013 and 31 December 2016. The patients will be identified searching the hospitals administrative patient system for the procedure code thoracocentesis (KTGA30).
Departments of Respiratory Medicine at Zealand University Hospital, Roskilde and Naestved Hospital, Region Zealand, Denmark, participate in this study. Both hospitals are a large tertiary hospital with specialised functions. Patients older than 16 years are included, irrespective of smoking history and comorbidities, if both thoracocentesis, chest x-ray and a CT-scanning are performed. Exclusion criteria are previously diagnosed lung cancer, thoracic malignancy or incomplete data.
Data Relevant data on demographics, descriptive data, symptoms, medical history and diagnostic workup will be extracted from electronic medical records, and registered in the individual patient's case report file (CRF). The CRF is stored using Excel on an encrypted USB-key, the USB-key will be stored behind double lock (room plus cupboard). Background-variables will be utilised to describe the study population and for explorative research. Only study coordinators will have access to data. Computers, as well as a back-up, will be stored and kept in a locked cupboard in a locked room. Only study coordinators possess relevant keys.
Statistics Data will be presented as frequencies and/or mean ± standard deviation (SD). Test characteristics will be compared using McNemar's test with a Bonferroni correction. An alpha level of 0.05 is considered significant. Test characteristics for thoracocentesis, chest x-ray and CT-scanning and the combination of the three will be calculated. Test characteristics are true positive, true negative, false positive, false negative, sensitivity, specificity, likelihood ratio+, likelihood ratio-, positive predictive value, negative predictive value and diagnostic accuracy.
The combined sensitivity of two parallel tests will be calculated using the formula:
The sensitivity of test A + sensitivity of test B - (sensitivity of test A x sensitivity of test B)
The combined specificity for two parallel tests will be calculated using the formula:
The specificity of test A x specificity of test B
The combined sensitivity of three parallel tests will be calculated using the formula:
The sensitivity of test A + sensitivity of test B + sensitivity of test C - (sensitivity of test A x sensitivity of test B x sensitivity of test C)
The combined specificity for three parallel tests will be calculated using the formula:
The specificity of test A x specificity of test B x sensitivity of test C For data analysis, we use STATA (StataCorp LLC, Version 15.0, College Station, Texas, USA).
Ethics The study is retrospective and observational and thus will not affect the included patients. Before any study-related activity, the protocol and study must be approved by the Danish Data Protection Agency and the local Committee on Biomedical Research Ethics. All results will be stored and analysed by computer, and the investigators secure the patients' anonymity according to the national laws. The data are anonymized and stored after completion of the study and data containing personal identification numbers will be kept behind double-lock at the department.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Computed tomography
The diagnostic power to discriminate malignant from nonmalignant causes of e pleural effusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chest X-ray and
* CT-scanning are performed
Exclusion Criteria
* Other thoracic malignancy
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Naestved Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Simon Reuter
Ph.d.student
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Naestved Hospital
Næstved, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CT-UPE
Identifier Type: -
Identifier Source: org_study_id